Form 4: Coherus BioSciences Executive Acquires Stock Options and Disposes of Shares for Tax Obligations

Paul Reider, Chief Commercial Officer of Coherus BioSciences, acquired 160,000 stock options and disposed of 2,277 shares to cover tax liabilities.

Summary

• Paul Reider, the Chief Commercial Officer of Coherus BioSciences, engaged in transactions involving the company's stock.
• On January 3, 2025, Reider was granted 160,000 stock options with an exercise price of $1.66.
• These options vest over time, with 25% vesting after one year and the remainder vesting monthly over the following 48 months.
• On January 4, 2025, 2,277 shares were automatically withheld to cover tax obligations related to the vesting of restricted stock units.
• The price of the shares withheld was $1.66 per share.
• Following these transactions, Reider directly owns 86,927 shares of Coherus BioSciences.

Sentiment

Score: 6

Explanation: The document reflects standard executive compensation practices. While the share disposal might be seen as slightly negative, it's for tax purposes and is not unusual. The stock option grant is a positive incentive.

Positives

• The granting of stock options to a key executive like the Chief Commercial Officer can be seen as a positive incentive for future performance.
• The vesting schedule of the options encourages long-term commitment from the executive.

Negatives

• The disposal of shares, even for tax purposes, could be perceived negatively by some investors, although it is a common practice.

Risks

• The vesting of stock options is contingent on the executive's continued employment with the company.
• The value of the stock options is dependent on the future performance of the company's stock price.

Future Outlook

The stock options will vest over time, subject to the executive's continued service with the company.

Management Comments

• No direct quotes from management are included in this document.

Industry Context

This type of transaction is common for executives in publicly traded companies as part of their compensation packages and to align their interests with shareholders.

Comparison to Industry Standards

• Stock option grants and tax-related share disposals are standard practices in executive compensation across the biotechnology industry.
• Companies like Amgen, Gilead, and Biogen also use stock options as part of their executive compensation packages.
• The vesting schedule of the options is also typical, with a mix of cliff vesting and monthly vesting.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive incentive for the executive.
• The share disposal for tax purposes is unlikely to have a significant impact on stakeholders.

Key Dates

Keywords

stock options, insider trading, executive compensation, share disposal, vesting, Coherus BioSciences, CHRS, Paul Reider